These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 30060279)

  • 1. [Update ESC-Guideline 2017: Dual Antiplatelet Therapy].
    Massberg S; Polzin A
    Dtsch Med Wochenschr; 2018 Aug; 143(15):1090-1093. PubMed ID: 30060279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
    Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
    Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Focused update on dual antiplatelet treatment : ESC guidelines 2017].
    Schäfer A; Bauersachs J
    Herz; 2017 Dec; 42(8):739-745. PubMed ID: 29043405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy.
    Sra S; Tan MK; Mehta SR; Fisher HN; Déry JP; Welsh RC; Eisenberg MJ; Overgaard CB; Rose BF; Siega AJ; Cheema AN; Wong BY; Henderson MA; Lutchmedial S; Lavi S; Goodman SG; Yan AT;
    Am Heart J; 2016 Oct; 180():82-9. PubMed ID: 27659886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events.
    Dobesh PP; Finks SW; Trujillo TC
    Clin Ther; 2020 Oct; 42(10):2084-2097. PubMed ID: 32873416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual antiplatelet therapy after coronary drug-eluting stent implantation in China: A large single center study.
    Xu JJ; Gao Z; Zhang Y; Gao LJ; Chen J; Qiao SB; Gao RL; Yang YJ; Xu B; Yuan JQ
    Catheter Cardiovasc Interv; 2018 Feb; 91(S1):566-572. PubMed ID: 29359390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.
    Paravattil B; Elewa H
    J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):347-355. PubMed ID: 28587584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
    Wimmer NJ; Dufour AB; Cho K; Gagnon DR; Quach L; Ly S; Do JM; Ostrowski S; Michael Gaziano J; Faxon DP; Kinlay S
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1176-1184. PubMed ID: 27860195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies.
    Bavishi C; Koulova A; Bangalore S; Sawant A; Chatterjee S; Ather S; Valencia J; Sarafoff N; Rubboli A; Airaksinen JK; Lip GY; Tamis-Holland JE
    Catheter Cardiovasc Interv; 2016 Jul; 88(1):E12-22. PubMed ID: 26354765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Costa F; van Klaveren D; James S; Heg D; Räber L; Feres F; Pilgrim T; Hong MK; Kim HS; Colombo A; Steg PG; Zanchin T; Palmerini T; Wallentin L; Bhatt DL; Stone GW; Windecker S; Steyerberg EW; Valgimigli M;
    Lancet; 2017 Mar; 389(10073):1025-1034. PubMed ID: 28290994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy.
    Fosbol EL; Wang TY; Li S; Piccini J; Lopes RD; Mills RM; Klaskala W; Thomas L; Roe MT; Peterson ED
    Am Heart J; 2013 Nov; 166(5):864-70. PubMed ID: 24176442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study.
    Bardají A; Leal M; Arrarte V; Garcia-Moll X; Pérez de Isla L; Bueno H
    Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 27885830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents.
    Yu J; Baber U; Mastoris I; Dangas G; Sartori S; Steg PG; Cohen DJ; Giustino G; Chandrasekhar J; Ariti C; Witzenbichler B; Henry TD; Kini AS; Krucoff MW; Gibson CM; Chieffo A; Moliterno DJ; Colombo A; Pocock S; Mehran R
    JACC Cardiovasc Interv; 2016 Jul; 9(14):1461-9. PubMed ID: 27478113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High platelet reactivity--the challenge of prolonged anticoagulation therapy after ACS.
    Brouwer MA; Jaspers Focks J; Verheugt FW
    Thromb Haemost; 2013 May; 109(5):799-807. PubMed ID: 23426079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy?
    Fluschnik N; Becher PM; Schnabel R; Blankenberg S; Westermann D
    Herz; 2018 Feb; 43(1):20-25. PubMed ID: 29188358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.
    Ariotti S; Adamo M; Costa F; Patialiakas A; Briguori C; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Ferlini M; Vranckx P; Valgimigli M;
    JACC Cardiovasc Interv; 2016 Mar; 9(5):426-36. PubMed ID: 26965932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention.
    Koskinas KC; Räber L; Zanchin T; Pilgrim T; Stortecky S; Hunziker L; Blöchlinger S; Billinger M; Gartwyl F; Moro C; Moschovitis A; Jüni P; Heg D; Windecker S
    JACC Cardiovasc Interv; 2016 Jul; 9(14):1473-83. PubMed ID: 27478115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th Anniversary Overview.
    Rubboli A; Faxon DP; Juhani Airaksinen KE; Schlitt A; Marín F; Bhatt DL; Lip GY
    Thromb Haemost; 2014 Dec; 112(6):1080-7. PubMed ID: 25298351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials.
    Pandit A; Giri S; Hakim FA; Fortuin FD
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):34-40. PubMed ID: 24753084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    Camaro C; Damen SA; Brouwer MA; Kedhi E; Lee SW; Verdoia M; Barbieri L; Rognoni A; van T Hof AW; Ligtenberg E; de Boer MJ; Suryapranata H; De Luca G
    Am Heart J; 2016 Aug; 178():37-44. PubMed ID: 27502850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.